NASDAQ:KALVKalvista Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kalvista Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.67 +0.22 (+1.77 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$12.00Now: $12.67▼$12.7850-Day Range$9.83MA: $11.83▼$12.9752-Week Range$5.61Now: $12.67▼$18.96Volume2,566 shsAverage Volume133,921 shsMarket Capitalization$226.11 millionP/E RatioN/ADividend YieldN/ABeta2.37 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingKalvista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.33, Kalvista Pharmaceuticals has a potential upside of 125.4% from its current price of $12.57.Amount of Analyst CoverageKalvista Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesKalvista Pharmaceuticals has received 289 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKalvista Pharmaceuticals has received 201 “underperform” votes. (Add your “underperform” vote.)Community SentimentKalvista Pharmaceuticals has received 58.98% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kalvista Pharmaceuticals and other stocks. Vote “Outperform” if you believe KALV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KALV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKalvista Pharmaceuticals does not currently pay a dividend.Dividend GrowthKalvista Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kalvista Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 21.60% of the stock of Kalvista Pharmaceuticals is held by insiders.Percentage Held by Institutions87.78% of the stock of Kalvista Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kalvista Pharmaceuticals are expected to decrease in the coming year, from ($2.62) to ($3.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kalvista Pharmaceuticals is -7.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kalvista Pharmaceuticals is -7.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKalvista Pharmaceuticals has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.48 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KALV Previous Symbol CUSIPN/A CIK1348911 Webwww.kalvista.com Phone857-999-0075Debt Debt-to-Equity RatioN/A Current Ratio11.49 Quick Ratio11.49Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$12.69 million Price / Sales17.82 Cash FlowN/A Price / Cash FlowN/A Book Value$4.69 per share Price / Book2.70Profitability EPS (Most Recent Fiscal Year)($1.64) Net Income$-29,120,000.00 Net Margins-229.45% Return on Equity-31.21% Return on Assets-27.25%Miscellaneous Employees33 Outstanding Shares17,846,000Market Cap$226.11 million Next Earnings Date9/14/2020 (Estimated) OptionableNot Optionable $12.67 +0.22 (+1.77 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive KALV News and Ratings via Email Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Kalvista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions How has Kalvista Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)? Kalvista Pharmaceuticals' stock was trading at $8.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KALV shares have increased by 42.1% and is now trading at $12.59. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Kalvista Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kalvista Pharmaceuticals. When is Kalvista Pharmaceuticals' next earnings date? Kalvista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, September 14th 2020. View our earnings forecast for Kalvista Pharmaceuticals. How were Kalvista Pharmaceuticals' earnings last quarter? Kalvista Pharmaceuticals Inc (NASDAQ:KALV) announced its earnings results on Wednesday, July, 1st. The specialty pharmaceutical company reported ($0.37) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.65) by $0.28. The specialty pharmaceutical company earned $3.82 million during the quarter, compared to analyst estimates of $2.05 million. Kalvista Pharmaceuticals had a negative net margin of 229.45% and a negative return on equity of 31.21%. View Kalvista Pharmaceuticals' earnings history. What price target have analysts set for KALV? 4 brokers have issued 12 month price objectives for Kalvista Pharmaceuticals' stock. Their forecasts range from $25.00 to $30.00. On average, they anticipate Kalvista Pharmaceuticals' share price to reach $28.33 in the next year. This suggests a possible upside of 125.0% from the stock's current price. View analysts' price targets for Kalvista Pharmaceuticals. Has Kalvista Pharmaceuticals been receiving favorable news coverage? Media coverage about KALV stock has been trending extremely negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kalvista Pharmaceuticals earned a news impact score of -4.0 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Kalvista Pharmaceuticals. Are investors shorting Kalvista Pharmaceuticals? Kalvista Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 391,800 shares, an increase of 24.2% from the June 15th total of 315,500 shares. Based on an average daily trading volume, of 137,700 shares, the days-to-cover ratio is currently 2.8 days. Approximately 3.1% of the company's stock are sold short. View Kalvista Pharmaceuticals' Short Interest. Who are some of Kalvista Pharmaceuticals' key competitors? Some companies that are related to Kalvista Pharmaceuticals include Cara Therapeutics (CARA), Phibro Animal Health (PAHC), Dynavax Technologies (DVAX), ORIC Pharmaceuticals (ORIC), Endo International (ENDP), Trillium Therapeutics (TRIL), Provention Bio (PRVB), Vectura Group (VEGPF), Frequency Therapeutics (FREQ), Assembly Biosciences (ASMB), Nkarta (NKTX), Kadmon (KDMN), Legend Biotech (AMTI), Passage Bio (KROS) and BIOFRONTERA AG/ADR (BFRA). View all competitors. What other stocks do shareholders of Kalvista Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Cara Therapeutics (CARA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), Crispr Therapeutics (CRSP), Viking Therapeutics (VKTX), Amarin (AMRN) and BioCryst Pharmaceuticals (BCRX). Who are Kalvista Pharmaceuticals' key executives? Kalvista Pharmaceuticals' management team includes the following people: Mr. Thomas Andrew Crockett, CEO & Director (Age 44)Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 53)Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 56)Mr. John B. McKune, VP of Fin. (Age 43)Dr. Edward P. Feener, Chief Scientific Officer (Age 59) What is Kalvista Pharmaceuticals' stock symbol? Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV." Who are Kalvista Pharmaceuticals' major shareholders? Kalvista Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (9.88%), Ikarian Capital LLC (6.24%), Logos Global Management LP (3.15%), International Biotechnology Trust PLC (0.99%), Bank of New York Mellon Corp (0.24%) and Goldman Sachs Group Inc. (0.21%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View institutional ownership trends for Kalvista Pharmaceuticals. Which institutional investors are selling Kalvista Pharmaceuticals stock? KALV stock was sold by a variety of institutional investors in the last quarter, including International Biotechnology Trust PLC, FMR LLC, Alps Advisors Inc., Algert Global LLC, UBS Group AG, and Bank of America Corp DE. Company insiders that have sold Kalvista Pharmaceuticals company stock in the last year include Christopher Yea, and Thomas Andrew Crockett. View insider buying and selling activity for Kalvista Pharmaceuticals. Which institutional investors are buying Kalvista Pharmaceuticals stock? KALV stock was bought by a variety of institutional investors in the last quarter, including Logos Global Management LP, Ikarian Capital LLC, Goldman Sachs Group Inc., California Public Employees Retirement System, Dupont Capital Management Corp, Trexquant Investment LP, Quantitative Systematic Strategies LLC, and Bank of New York Mellon Corp. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha, and Daniel B Soland. View insider buying and selling activity for Kalvista Pharmaceuticals. How do I buy shares of Kalvista Pharmaceuticals? Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Kalvista Pharmaceuticals' stock price today? One share of KALV stock can currently be purchased for approximately $12.59. How big of a company is Kalvista Pharmaceuticals? Kalvista Pharmaceuticals has a market capitalization of $224.68 million and generates $12.69 million in revenue each year. The specialty pharmaceutical company earns $-29,120,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe. What is Kalvista Pharmaceuticals' official website? The official website for Kalvista Pharmaceuticals is www.kalvista.com. How can I contact Kalvista Pharmaceuticals? Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
